Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Diamyd Therapeutics AB |
---|---|
Information provided by: | Diamyd Therapeutics AB |
ClinicalTrials.gov Identifier: | NCT00751842 |
The purpose of this study is to determine whether Diamyd (rhGAD65 formulated in alum) is effective in preserving the body's own insulin producing capacity in patients recently diagnosed with type 1 diabetes.
Condition | Intervention | Phase |
---|---|---|
Type 1 Diabetes Mellitus |
Drug: rhGAD65 Drug: Placebo |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Parallel Assignment, Efficacy Study |
Official Title: | A Phase III, 3-Arm, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Investigate the Impact of Diamyd on the Progression of Diabetes in Patients Newly Diagnosed With Type 1 Diabetes Mellitus (USA) |
Estimated Enrollment: | 320 |
Study Start Date: | August 2008 |
Estimated Study Completion Date: | October 2011 |
Estimated Primary Completion Date: | October 2010 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
A: Active Comparator
This arm will receive 2 subcutaneous injections with 20 µg Diamyd on days 1 and 30, i.e., 1 prime and 1 booster dose, followed by 2 additional single doses with Diamyd 20 µg on days 90 and 270.
|
Drug: rhGAD65
Diamyd (rhGAD65) 20 µg injected subcutaneously at days 1, 30, 90 and 270.
|
B: Active Comparator
This arm will receive 2 subcutaneous injections with 20 µg Diamyd on days 1 and 30, i.e., 1 prime and 1 booster dose, followed by 2 additional single doses with placebo on days 90 and 270.
|
Drug: rhGAD65
Diamyd (rhGAD65) 20 µg injected subcutaneously at days 1 and 30, followed by placebo injections at days 90 and 270.
|
C: Placebo Comparator
This arm will receive 4 injections of placebo, 1 each on days 1, 30, 90 and 270.
|
Drug: Placebo
Placebo injected subcutaneously at days 1, 30, 90 and 270.
|
Ages Eligible for Study: | 16 Years to 20 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Main Inclusion Criteria:
Male and female patients between 16 and 20 years of age*
Main Exclusion Criteria:
Contact: Sharon Wolf | 201-587-0500 | swolf@tklresearch.com |
United States, Arkansas | |
SFE Superior Research | Recruiting |
Rogers, Arkansas, United States, 72758 | |
Principal Investigator: Nadine H. Alex, MD | |
United States, California | |
Rady Children's Hospital | Recruiting |
San Diego, California, United States, 92123 | |
Principal Investigator: Ron Newfield, MD | |
United States, Florida | |
Clinical Trials Management | Recruiting |
Boca Raton, Florida, United States, 33486 | |
Principal Investigator: Mark Frager, MD | |
Clinical Trials Management | Recruiting |
Pembroke Pines, Florida, United States, 33024 | |
Principal Investigator: Fidel Henriquez, MD | |
Clinical Trials Management | Recruiting |
Orlando, Florida, United States, 32803 | |
Principal Investigator: William Hall, MD | |
Clinical Trials Management | Recruiting |
Daytona Beach, Florida, United States, 33211 | |
Principal Investigator: Timothy Valk, MD | |
Clinical Trials Management | Recruiting |
Orlando, Florida, United States, 32835 | |
Principal Investigator: Kimberley Bourne, MD | |
Clinical Trials Management | Recruiting |
Winter Park, Florida, United States, 32789 | |
Principal Investigator: Victor Roberts, MD | |
Clinial Trials management | Recruiting |
Jupiter, Florida, United States, 33458 | |
Principal Investigator: Gary Pepper, MD | |
United States, Idaho | |
Rocky Mountain Diabetes and Osteoporosis Center | Recruiting |
Idaho Falls, Idaho, United States, 83404 | |
Principal Investigator: Carl D. Vance, MD | |
United States, Kentucky | |
Dept. of Veteran Affairs Medical Center | Recruiting |
Lexington, Kentucky, United States, 40502 | |
Principal Investigator: Dennis Karounos, MD | |
University of Louisville Research Foundation | Recruiting |
Louisville, Kentucky, United States, 40202 | |
Principal Investigator: Kupper Wintergerst, MD | |
United States, Maryland | |
University of Maryland Medical Center | Recruiting |
Baltimore, Maryland, United States, 21201 | |
Principal Investigator: Debra Counts, MD | |
United States, Michigan | |
Alzohaili Medical Consultants | Recruiting |
Dearborn, Michigan, United States, 48126 | |
Principal Investigator: Opada Alzohaili, MD | |
United States, Nevada | |
Kathryn Eckert | Recruiting |
Reno, Nevada, United States, 89502 | |
Principal Investigator: Kathryn Eckert, MD | |
United States, New York | |
SUNY Institute for Human Performance | Recruiting |
Syracuse, New York, United States, 13210 | |
Principal Investigator: Ruth Weinstock, MD | |
University of Rochester | Recruiting |
Rochester, New York, United States, 14642 | |
Principal Investigator: Nicholas Jospe, MD | |
United States, Oklahoma | |
University of Oklahoma, Schustermann Center Clinic | Recruiting |
Tulsa, Oklahoma, United States, 74135 | |
Principal Investigator: David Jelley, MD | |
United States, Texas | |
CHRISTUS Santa Rosa Children's Hospital | Not yet recruiting |
San Antonio, Texas, United States, 78207 | |
Principal Investigator: William Rogers, MD | |
United States, Virginia | |
Virginia Commonwealth University | Recruiting |
Richmond, Virginia, United States, 23219 | |
Principal Investigator: Gary Francis, MD |
Principal Investigator: | Jerry Palmer, Professor | University of Washington |
Responsible Party: | Diamyd Therapeutics AB ( Managing Director ) |
Study ID Numbers: | D/P3/07/5 |
Study First Received: | September 11, 2008 |
Last Updated: | April 3, 2009 |
ClinicalTrials.gov Identifier: | NCT00751842 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Diabetes Juvenile Diabetes Diabetes type 1 Autoimmune Diabetes Insulin dependent Diabetes Type 1 diabetes |
Type 1 diabetes mellitus Diamyd rhGAD65 GAD GAD-alum |
Aluminum sulfate Autoimmune Diseases Metabolic Diseases Diabetes Mellitus, Type 1 Disease Progression Diabetes Mellitus |
Endocrine System Diseases Diabetes Mellitus Type 1 Endocrinopathy Glucose Metabolism Disorders Metabolic Disorder Insulin |
Autoimmune Diseases Metabolic Diseases Immune System Diseases Diabetes Mellitus, Type 1 |
Diabetes Mellitus Endocrine System Diseases Glucose Metabolism Disorders |